|
287 Companies |
|
339 Products |
|
339 Products |
|
208 Mechanisms of Action |
|
11 Trials |
|
3337 News |
|
| «12...678910111213141516...6869» |
- | HuMax-EGFR (zalutumumab) / Genmab
Trial completion: DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC (clinicaltrials.gov) - Nov 25, 2016
P3, N=619, Completed, Sponsor: Danish Head and Neck Cancer Group
Active, not recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial primary completion date, Combination therapy: S-1 in Combination With Abraxane in Treating Cholangiocarcinoma (clinicaltrials.gov) - Nov 23, 2016
P2, N=2, Terminated, Sponsor: Yuhong Li
Active, not recruiting --> Completed Trial primary completion date: Oct 2016 --> Dec 2017
- Signifor (pasireotide) / Recordati
Trial primary completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 18, 2016
P1, N=13, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Oct 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Zybrestat (fosbretabulin) / Oncotelic
Biomarker, Trial completion, Enrollment change: Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study (clinicaltrials.gov) - Nov 17, 2016
P2, N=7, Completed, Sponsor: Mateon Therapeutics
Trial primary completion date: Dec 2016 --> Dec 2017 Enrolling by invitation --> Completed | N=20 --> 7
- Enrollment closed, Trial primary completion date: HIFU-FA-001: Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (clinicaltrials.gov) - Nov 16, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: David R. Brenin, MD
Enrolling by invitation --> Completed | N=20 --> 7 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Sep 2017
- | veliparib (ABT-888) / AbbVie
Trial completion, Monotherapy, BRCA Biomarker, PARP Biomarker: Veli-BRCA: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (clinicaltrials.gov) - Nov 16, 2016
P1/2, N=49, Completed, Sponsor: Vejle Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Sep 2017 Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Enrollment change, Trial withdrawal, Metastases: Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Nov 15, 2016
P1/2, N=0, Withdrawn, Sponsor: Philipps University Marburg Medical Center
Active, not recruiting --> Completed N=18 --> 0 | Recruiting --> Withdrawn
- |||| Javlor (vinflunine) / Pierre Fabre
Trial primary completion date, Combination therapy, Metastases: Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer (clinicaltrials.gov) - Nov 14, 2016
P3, N=530, Recruiting, Sponsor: Pierre Fabre Medicament
N=18 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jun 2015 --> Jan 2017
- Trial completion, Metastases: NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - Nov 8, 2016
P2, N=10, Completed, Sponsor: Angiodynamics, Inc.
Trial primary completion date: Jun 2015 --> Jan 2017 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=26, Completed, Sponsor: Angiodynamics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jan 2013
- Trial completion, Surgery, Metastases: Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO) (clinicaltrials.gov) - Nov 7, 2016
P=N/A, N=15, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jan 2013 Active, not recruiting --> Completed
- Ojjaara (momelotinib) / GSK
Phase classification, Metastases: Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Nov 7, 2016
P1b, N=30, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Phase classification: P1 --> P1b
- Enrollment closed: Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome (clinicaltrials.gov) - Nov 7, 2016
P2, N=3, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Phase classification: P1 --> P1b Recruiting --> Active, not recruiting
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment closed, Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Nov 2, 2016
P1, N=9, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017
- | Tabrecta (capmatinib) / Incyte, Novartis, buparlisib (AN2025) / Adlai Nortye
Enrollment closed, Enrollment change, Combination therapy: Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Nov 2, 2016
P1/2, N=42, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017 Recruiting --> Active, not recruiting | N=63 --> 42
- Trial primary completion date: Whipple Procedure: Standard of Care vs. Thunderbeat (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=60, Enrolling by invitation, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | N=63 --> 42 Trial primary completion date: Aug 2016 --> May 2018
- Trial completion: Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=33, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Trial primary completion date: Aug 2016 --> May 2018 Recruiting --> Completed
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment closed, Enrollment change: Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors (clinicaltrials.gov) - Nov 1, 2016
P1, N=1, Active, not recruiting, Sponsor: Edward Ziga
Recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 1
- || SGN-CD70A / Pfizer
Trial primary completion date: Safety Study of SGN-CD70A in Cancer Patients (clinicaltrials.gov) - Nov 1, 2016
P1, N=95, Recruiting, Sponsor: Seattle Genetics, Inc.
Recruiting --> Active, not recruiting | N=20 --> 1 Trial primary completion date: Jun 2016 --> Mar 2017
- cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Oct 28, 2016
P1, N=27, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Jun 2016 --> Mar 2017 N=60 --> 27
- Aqupla (nedaplatin) / Simcere
Trial primary completion date, Head-to-Head, Metastases: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 28, 2016
P3, N=402, Completed, Sponsor: Sun Yat-sen University
N=60 --> 27 Trial primary completion date: Mar 2012 --> May 2014
- nintedanib / Generic mfg.
Trial completion: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Oct 28, 2016
P2, N=36, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Mar 2012 --> May 2014 Active, not recruiting --> Completed
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Phase classification, Combination therapy, Metastases: QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 27, 2016
P1b/2, N=138, Completed, Sponsor: NantCell, Inc.
Active, not recruiting --> Completed Phase classification: P1/2 --> P1b/2
- ||| Trial completion: Prospective Trial to Compare the Clinical Efficiency of G-EYE (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=1000, Completed, Sponsor: Smart Medical Systems Ltd.
Phase classification: P1/2 --> P1b/2 Recruiting --> Completed
- ||| carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Combination therapy, Metastases: ABOUND 70+: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (clinicaltrials.gov) - Oct 26, 2016
P4, N=280, Active, not recruiting, Sponsor: Celgene Corporation
Recruiting --> Completed Recruiting --> Active, not recruiting
- pegvorhyaluronidase alfa (PEGPH20) / Halozyme, Erbitux (cetuximab) / Eli Lilly
Trial completion, Enrollment change, Trial primary completion date: Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=2, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Completed | N=10 --> 2 | Trial primary completion date: Sep 2017 --> Sep 2016
- || everolimus / Generic mfg.
Trial primary completion date, Metastases: Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) (clinicaltrials.gov) - Oct 25, 2016
P4, N=80, Active, not recruiting, Sponsor: iOMEDICO AG
Recruiting --> Completed | N=10 --> 2 | Trial primary completion date: Sep 2017 --> Sep 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- metformin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date: OVMET: Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer (clinicaltrials.gov) - Oct 25, 2016
P1, N=20, Recruiting, Sponsor: University Medical Center Groningen
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Nov 2016 --> Mar 2017
- temozolomide / Generic mfg.
Trial completion, Trial primary completion date: MET-PET for Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Oct 21, 2016
P0, N=20, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Nov 2016 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2016
- Trial primary completion date: Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy (clinicaltrials.gov) - Oct 19, 2016
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2016 Trial primary completion date: Jan 2017 --> Jan 2018
- | Signifor (pasireotide) / Recordati
Trial completion, Enrollment change, Trial primary completion date: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Oct 19, 2016
P1, N=22, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jan 2017 --> Jan 2018 Active, not recruiting --> Completed | N=32 --> 22 | Trial primary completion date: Apr 2016 --> Sep 2014
- |||| temozolomide / Generic mfg.
Trial primary completion date: EF-14: Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Oct 18, 2016
P3, N=700, Active, not recruiting, Sponsor: NovoCure Ltd.
Active, not recruiting --> Completed | N=32 --> 22 | Trial primary completion date: Apr 2016 --> Sep 2014 Trial primary completion date: Jul 2016 --> Dec 2016
- | Aqupla (nedaplatin) / Simcere
Trial completion, Trial primary completion date, Head-to-Head, Metastases: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 18, 2016
P3, N=402, Completed, Sponsor: Sun Yat-sen University
Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Mar 2012
- Trial completion, Trial primary completion date, Surgery: Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Oct 17, 2016
P1, N=50, Completed, Sponsor: John Sampson
Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Mar 2012 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2014
- | oxaliplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Combination Treatment for Advanced Liver Cancer (clinicaltrials.gov) - Oct 13, 2016
P3, N=98, Completed, Sponsor: Shanghai Zhongshan Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2014 Active, not recruiting --> Completed
- everolimus / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers (clinicaltrials.gov) - Oct 12, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: St. Joseph's Healthcare Hamilton
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion, Enrollment change: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Oct 11, 2016
P2, N=12, Completed, Sponsor: Camurus AB
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=24 --> 12
- sirolimus / Generic mfg.
Trial completion, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 4, 2016
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=24 --> 12 Active, not recruiting --> Completed | N=30 --> 18
- MK-2206 / Merck (MSD)
Enrollment change, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 30, 2016
P2, N=12, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | N=30 --> 18 N=45 --> 12
- Yervoy (ipilimumab) / BMS
Phase classification, Monotherapy: Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection (clinicaltrials.gov) - Sep 30, 2016
P1b, N=12, Completed, Sponsor: Bristol-Myers Squibb
N=45 --> 12 Phase classification: P1 --> P1b
- amatuximab (MORAb-009) / Eisai
Trial primary completion date: MORAb-009-006: A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers (clinicaltrials.gov) - Sep 30, 2016
P1, N=6, Completed, Sponsor: Morphotek
Phase classification: P1 --> P1b Trial primary completion date: Aug 2013 --> Mar 2013
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors (clinicaltrials.gov) - Sep 30, 2016
P0, N=6, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Aug 2013 --> Mar 2013 Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Jan 2017 --> May 2016
- NanO2 (perflenapent) / NuvOx Pharma
Enrollment closed, Phase classification, Trial primary completion date: The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (clinicaltrials.gov) - Sep 26, 2016
P1b, N=25, Active, not recruiting, Sponsor: NuvOx Pharma Pty Ltd
Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Jan 2017 --> May 2016 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b | Trial primary completion date: Jun 2015 --> Sep 2017
- temozolomide / Generic mfg.
Trial completion, Trial primary completion date: O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy (clinicaltrials.gov) - Sep 23, 2016
P2, N=100, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b | Trial primary completion date: Jun 2015 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2010 --> Jul 2009
- Trial completion: Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants (clinicaltrials.gov) - Sep 23, 2016
P1, N=16, Completed, Sponsor: Yale University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2010 --> Jul 2009 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy (clinicaltrials.gov) - Sep 23, 2016
P=N/A, N=469, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=650 --> 469 | Initiation date: Jul 2005 --> Apr 2002 | Trial primary completion date: Nov 2017 --> Aug 2016
- Trial completion, Trial primary completion date: Localization of Nonpalpable Breast Lesions (clinicaltrials.gov) - Sep 23, 2016
P=N/A, N=410, Completed, Sponsor: Rigshospitalet, Denmark
Active, not recruiting --> Completed | N=650 --> 469 | Initiation date: Jul 2005 --> Apr 2002 | Trial primary completion date: Nov 2017 --> Aug 2016 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Feb 2016
- | Trial completion: Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (clinicaltrials.gov) - Sep 23, 2016
P1, N=49, Completed, Sponsor: Dr. Reddy's Laboratories Limited
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Feb 2016 Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial initiation date, Trial primary completion date: Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: University of Utah
Recruiting --> Completed Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jan 2018 --> Jan 2022
- | avasopasem manganese (GC4419) / Galera Therap
Trial completion, Combination therapy: A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck (clinicaltrials.gov) - Sep 22, 2016
P1, N=30, Completed, Sponsor: Galera Therapeutics, Inc.
Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jan 2018 --> Jan 2022 Active, not recruiting --> Completed